Jennifer Miller, PA
Physician Assistant · Mill Hall, PANPI 1437437233
Payments from drug & device makers
Across 482 payments — averaging $13.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$969
- AbbVie$744
- Philips North America LLC$682
- Pfizer$431
- Boehringer Ingelheim$296
- plus $2K from 24 others
What the payments were for
- Food & beverage$6,285100%
- Education$20%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 89 | $1,291 |
| Lilly USA, LLC | 80 | $969 |
| AbbVie | 51 | $744 |
| Philips North America LLC | 76 | $682 |
| Pfizer | 25 | $431 |
| Boehringer Ingelheim | 22 | $296 |
| GSK | 17 | $254 |
| Johnson & Johnson | 35 | $224 |
| Amgen | 14 | $215 |
| AstraZeneca | 12 | $211 |
| Bayer | 12 | $160 |
| Dexcom, Inc. | 5 | $102 |
| Aimmune Therapeutics, Inc. | 5 | $87 |
| Shield Therapeutics Inc | 5 | $84 |
| E.r. Squibb & Sons, L.L.C. | 4 | $64 |
| Astellas Pharma US Inc | 3 | $60 |
| Abbott | 3 | $56 |
| Phathom Pharmaceuticals, Inc. | 3 | $56 |
| Electromed, Inc. | 2 | $51 |
| Eisai Inc. | 3 | $44 |
| Biogen | 3 | $42 |
| Exact Sciences | 2 | $36 |
| Amarin Pharma, Inc. | 2 | $26 |
| Kyowa Kirin, Inc. | 1 | $24 |
| Baxter Healthcare | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Grifols USA, LLC | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
| Sumitomo Pharma America, Inc. | 3 | $2 |
How this compares
$6,288 in reported general payments places this provider in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 662 | $239,822 |
| MounjaroTirzepatide | 158 | $179,736 |
| OzempicSemaglutide | 132 | $154,339 |
| JardianceEmpagliflozin | 241 | $124,254 |
| TrulicityDulaglutide | 89 | $107,143 |
| RybelsusSemaglutide | 65 | $65,651 |
| Breo ElliptaFluticasone/Vilanterol | 97 | $45,507 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 89 | $42,631 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $36,901 |
| LinzessLinaclotide | 47 | $33,144 |
| FarxigaDapagliflozin Propanediol | 65 | $29,045 |
| XareltoRivaroxaban | 21 | $28,236 |
| OxycontinOxycodone Hcl | 11 | $27,289 |
| JanuviaSitagliptin Phosphate | 72 | $24,418 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 40 | $23,958 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Olanzapine | $969 | $295,448510 claims |
| PfizerEliquis | $431 | $239,822662 claims |
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6 | $1,291 | $234,335210 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat | $296 | $167,240304 claims |
| GSKBreo Ellipta, Anoro Ellipta, Trelegy Ellipta, Incruse Ellipta | $254 | $132,911259 claims |
| AbbVieLinzess, Vraylar | $744 | $50,60261 claims |
| AstraZenecaFarxiga | $211 | $29,04565 claims |
| Johnson & JohnsonXarelto | $224 | $28,23621 claims |
| Astellas Pharma US IncMyrbetriq | $60 | $21,76562 claims |
| AmgenProlia | $215 | $18,39611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.
Other physician assistant in Mill Hall
- Erin CrownState College$1.5M
- Tricia BootsCranberry Twp$313K
- Melissa FerrariPhiladelphia$223K
- Jason OberdickWexford$206K
- Justine RobertsMurrysville$173K
- Allison BoydErie$163K
- Joshua TrbovichWashington$144K
- Daniel TelegaErie$124K
- Alvin KingcadePhiladelphia$101K
- Jeffrey CameronWashington$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.